Article
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site.
Cancer cell - 8 Feb 2021
Chen Shuo, Wu Jia-Le, Liang Ying, Tang Yi-Gang, Song Hua-Xin, Wu Li-Li, Xing Yang-Fei, Yan Ni, Li Yun-Tong, Wang Zheng-Yuan, Xiao Shu-Jun, Lu Xin, Chen Sai-Juan, Lu Min
Abstract excerpt
TP53 is the most frequently mutated gene in cancer, yet these mutations remain therapeutically non-actionable. Major challenges in drugging p53 mutations include heterogeneous mechanisms of inactivation and the absence of broadly applicable allosteric sites. Here we report the identification of small molecules, including arsenic trioxide (ATO), an established agent in treating acute promyelocytic leukemia, as...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.